4 ms·
FDA's genesis was bound pretty close to marketing. If you wanted to sell "Aunt Eliza's Magic Elixir" and claim that it "cures all ails: backaches, headaches, e
by wyldfire 10y ago
FDA's genesis was bound pretty close to marketing. If you wanted to sell "Aunt Eliza's Magic Elixir" and claim that it "cures all ails: backaches, headaches, etc", you are required to show evidence that validates those claims. See Pure Food and Drug Act.
FDA's responsibility is mutually exclusive with USPTO which would approve/deny patents based on "novelty".
- maxerickson 10y agoI'm not suggesting that the FDA could deny a patent. I'm suggesting that the FDA could simply refuse to approve the new version of a product. In the case where there are generics and the improvement is small, it doesn't matter if the company decides to take their ball and go home. It might be a fine line to walk, but the improvements to the Epipen don't seem to be very substantial (it's kind of hard to figure out what the improvements are with so much coverage of the recent events).
- wyldfire 10y agoWhat would be the basis on which they would deny a new product? If you were Mylan, you would bring suit. Courts would not side with the FDA, because they'd be wrong. The FDA's responsibility is dictated by legislation and there's nothing in the US Code that describes "you can't release new products if the new design isn't sufficiently improved." Legislators have all the power. If they can agree, they can say "Woo party free EpiPens for everyone, put it in the budget." FDA has some small amount of judgment they can apply within reason to restrict products that fail to comply with the law.
- maxerickson 10y agoThey could perhaps deny the application on the basis that the claimed benefits of the safety feature don't exist. https://www.law.cornell.edu/uscode/text/21/355 https://www.law.cornell.edu/uscode/text/21/355 (5) evaluated on the basis of the information submitted to him as part of the application and any other information before him with respect to such drug, there is a lack of substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the proposed labeling thereof; or (6) the application failed to contain the patent information prescribed by subsection Maybe it's a stretch, but a marginally safer but much less accessible product actually doesn't improve the situation for the public. I'm partly suggesting here that if the FDA doesn't have the authority, maybe they should.
- FireBeyond 10y agoAs someone who has worked with EpiPens for seven years now, administering them to patients weekly, if not more, it's very hard for me to find any claim of "improving the product" to be more than lip service. Certainly I don't consider the drug beyond active ingredient, but in the delivery mechanism (where they've also claimed "significant improvements and refinements", very little has changed. The shape of the container is a bit different, the 'window' to see the drug (to look for cloudiness or discoloration) is a little bigger (mind you, such a window is more akin to "empty space in product coloring and branding"). Certainly, I know some things might happen "behind the scenes". Maybe they found a more durable spring for the needle (not that was ever a problem), or such. But yes, I struggle to see it as anything more than patent extension. Which is why, after our relatively small county, which THROWS OUT $100,000 of EpiPens a year in the Medic One system (which we are mandated to carry by state law) is moving to train EMTs to draw up epi from $2.80 vials, themselves.